Gene Interference Vector and Iron Nanoparticle Composition for Ferroptosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer gene therapy and iron nanomaterials face challenges in achieving cancer cell specificity and efficacy due to cellular iron homeostasis mechanisms, which limit their clinical value in inducing ferroptosis in cancer cells.
Innovation Solution
A composition combining a gene interference vector, specifically a CRISPR/Cas13a or microRNA expression vector controlled by a cancer cell-specific promoter DMP, with iron nanoparticles like ferric oxide nanoparticles (Fe3O4) modified by Dimethylaminosulfanilide (DMSA), which targets and inhibits intracellular iron metabolism and reactive oxygen species-related genes, leading to increased iron ions and ROS levels in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If iron nanoparticles are used to induce ferroptosis in cancer cells, then anticancer efficacy is improved, but cellular iron homeostasis mechanisms limit the effectiveness
Solution Approach 1:
The invention divides the treatment approach into two distinct components: (1) iron nanoparticles that deliver iron ions to cancer cells, and (2) gene interference vectors that specifically knock down iron export genes (FPN and Lcn2). This segmentation allows each component to perform its specialized function while overcoming the limitations of using iron nanoparticles alone, as the gene interference component disables the cellular homeostasis mechanisms that would otherwise limit iron nanoparticle effectiveness.
Solution Approach 2:
The invention creates a composite therapeutic system combining iron nanoparticles with gene interference vectors (CRISPR/Cas13a or microRNA). This composite approach integrates two different mechanisms—physical iron delivery and genetic intervention—to achieve synergistic anticancer effects. The gene interference vector enhances the effectiveness of iron nanoparticles by preventing iron export, thereby maintaining elevated intracellular iron levels necessary for sustained ferroptosis.
2Adaptability or versatility
If gene therapy is used to control gene expression in cancer cells, then cancer cell specificity is improved, but gene control elements are complex in composition and low in efficiency
Solution Approach 1:
The invention uses cancer-specific promoters as intermediary elements that bridge the gap between gene delivery and cancer-specific expression. These promoters act as molecular switches that are activated only in cancer cells, enabling selective expression of the gene interference components (CRISPR/Cas13a or microRNA) specifically in cancer cells while sparing normal cells. This intermediary mechanism simplifies the control system compared to complex gene switches while maintaining high cancer cell specificity.
Solution Approach 2:
The invention changes the expression parameters of the gene interference components by controlling them with cancer-specific promoters. This parameter change ensures that the gene interference machinery (Cas13a or microRNA) is only expressed in cancer cells where the promoter is activated, thereby achieving cancer cell specificity without requiring complex gene switch compositions. The promoter acts as a simple yet effective control element that responds to cancer-specific cellular conditions.
3Reliability
If gene interference vector and iron nanoparticles are combined, then ferroptosis induction is improved, but complexity of treatment composition increases
Solution Approach 1:
The invention merges two therapeutic modalities—gene interference and iron nanoparticle therapy—into a single combined treatment composition. The gene interference vector (containing CRISPR/Cas13a or microRNA under cancer-specific promoter control) is administered together with iron nanoparticles. This merging creates a synergistic effect where the gene interference component disables iron export mechanisms while iron nanoparticles provide sustained iron supply, together inducing potent ferroptosis in cancer cells. The combined approach overcomes the limitations of each individual therapy while achieving reliable ferroptosis induction.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This combination effectively induces significant ferroptosis in cancer cells while sparing normal cells, demonstrating cancer cell specificity and broad-spectrum anticancer efficacy, with potential for novel cancer therapeutic agents.
Implementation Method 1
The Cas13a-gRNA or microRNA expressed by this vector can target and inhibit the expression of iron metabolism and reactive oxygen species-related genes in cancer cells
Implementation Method 2
the iron nanoparticles can be degraded to generate iron ions after entering cells
Implementation Method 3
When ferrous iron (Fe2+) exists together with peroxides and oxygen, ROS can be generated through the Fenton reaction
Implementation Method 4
high levels of ROS can cause irreversible cellular damage, leading to apoptosis, autophagy, and necrosis in various types of cancer cells
Implementation Method 5
Ferroptosis is dependent on intracellular iron, independent of other metals, and is morphologically, biochemically and genetically not related to other well-known regulated cell death types such as apoptosis, necrosis, necroptosis and autophagy
Data Source
AI summary
Disclosed in the present invention are a gene interference vector- and iron nanoparticle-based composition for killing cancer cells, and the use thereof. The composition comprises a gene interference vector and iron nanoparticles, wherein the gene interference vector is a CRISPR/Cas13a expression vector or microRNA expression vector controlled by a cancer cell specific promoter DMP, with the Cas13a-gRNA or microRNA expressed by the vector being able to inhibit, in a targeted manner, intracellular iron metabolism and the expression of reactive oxygen related genes, and the iron nanoparticles can be degraded after entering cells to produce iron ions and to increase the reactive oxygen level. The composition comprising the gene interference vector and the iron nanoparticles of the present invention can be used for preparing a new reagent for treating cancers.